ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Magnesium Protects Against Stroke, Heart Disease and Diabetes

Astaxanthin Is a Longevity Promoter

Meta-analysis links vitamin D deficiency with increased risk of mortality during 10.5 year median pe...

Prevent Or Reverse Diabetes: An Amazing Herbal Intervention

Exercise and Vitamin D Better Together for Heart Health

VIDEO: Essential Oils for Weight Loss

Can Valerian Root Help You Sleep Better?

Eight servings of veggies a day is clearly best for the heart

The Many Wonders of Calming Sandalwood Oil

Fighting Statin-Induced Diabetes with CoQ10

 
Print Page
Email Article

New Ampligen Findings to Be Featured at IACFS/ME Conference; FDA Decision on Drug Delayed Until May 25

  [ 6 votes ]   [ 1 Comment ]
www.ProHealth.com • February 19, 2009


An FDA ruling was expected this month on the investigational “antiviral/immune modulatory” drug Ampligen® - potentially the first to be approved for treatment of ‘chronic fatigue syndrome’ (ME/CFS).

As of Feb 18, however, Ampligen’s maker (Hemispherx Biopharma) revealed that the FDA has delayed the decision date to May 25. At the same time, Hemispherx also announced that its Medical Director, Dr. David Strayer, will be presenting “new Ampligen clinical data” at the IACFS/ME Science Conference in Reno, NV, March 12-15.

Strayer’s presentation, scheduled in Session 1 of the Professional Meeting:

“Will include new data from the ongoing treatment IND/compassionate study (AMP 511) as well as the completed well-controlled pivotal Phase III study (AMP 516).

“Individuals suffering with CFS are known to be at greater risk than age-matched healthy populations with respect to certain catastrophic events including cancer, sudden cardio-vascular death and suicidal ideation. The new data will evaluate the potential of Ampligen… to mitigate certain of these events. Data utilized will integrate serially performed immunologic lab panels and EKGs, as well as physical performance scores and medical records (including concomitant medications used to alleviate certain symptoms of CFS).

“Ampligen®, an experimental product, may modulate nature’s primary gateway to immune response, mediated by receptors termed “toll-like receptors” (TLRs). Many other immuno-modulators may work downstream from the TLRs immune “gateways” at so-called “checkpoints.” Since “checkpoints” are not normally part of nature’s own immune-defense surveillance apparatus, these alternative “checkpoint” strategies may be associated with unintended consequences including significant toxicities.”

What Is Ampligen?

Ampligen (AMPLIfied GENetic activity) - an “orphan drug” under development & testing for 30 years and still allowed only in specific clinical trial settings conducted under U.S. governmental authorization - is termed “a nucleic acid drug,” designed to “modulate” the body’s immune system. Its mechanism of action in ME/CFS “is not entirely clear,” but it is thought to act on two enzyme systems so as to help the immune system destroy viral RNA and speed the death of virus-affected cells. In particular it may “downregulate” an anti-viral pathway which research suggests has become “upregulated” in certain ME/CFS patients (the 2-5 Synthetase/RNase L anti-viral pathway).

A "Who's-Who" of the world’s leading ME/CFS specialists have participated in Ampligen trials over the years.




Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Ultra ATP+, Double Strength FibroSleep™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments Post a Comment

3 month extension
Posted by: outofstep
Feb 19, 2009
According to the Hemispherx press release the FDA has extended the NDA review date to May 25th
Reply Reply
 
NAD+ Ignite with Niagen

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Aches and Pains? A Simple Solution You'll Love Aches and Pains? A Simple Solution You'll Love
Carry a Massage Therapist in Your Pocket Carry a Massage Therapist in Your Pocket
Restore Youthful Cognition and Well-Being Restore Youthful Cognition and Well-Being
The Super Antioxidant for Brain, Joint and Heart Health The Super Antioxidant for Brain, Joint and Heart Health
The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map